Copyright
©2011 Baishideng Publishing Group Co.
World J Cardiol. May 26, 2011; 3(5): 153-164
Published online May 26, 2011. doi: 10.4330/wjc.v3.i5.153
Published online May 26, 2011. doi: 10.4330/wjc.v3.i5.153
Study design | Follow-up | Number of patients on clopidogrel with/without PPI | End point | Results | Ref. |
Population-based study | 6 yr | PPI: 572; no PPI: 2706 | Rehospitalization (due to AMI or angina); mortality | Rehospitalization in PPI vs no PPI groups: HR: 1.23 (95% CI: 1.07-1.41, P = 0.003); mortality: HR: 1.65 (95% CI: 1.35-2.01, P < 0.001) | Huang et al[20] |
Retrospective cohort study | 1 yr | Low PPI: 712; high PPI: 5.03%(?); without PPI: 4800 | MI | Acute MI rate: non-PPI: 1.38% (66/4800); low PPI exposure: 3.08% (22/712); high PPI exposure: 5.03% (?) (P < 0.05 for high vs no PPI use) | Pezalla et al[21] |
Retrospective nested case-control | 3 mo | Cases: 734 (PPI: 194); controls: 2057 (PPI: 424) | Death or readmitted for MI | Readmission for acute MI, adjusted OR 1.27 (95% CI: 1.03-1.57); pantoprazole OR: 1.02 (95% CI: 0.70-1.47); other PPIs (omeprazole, lansoprazole and rabeprazole) OR: 1.40 (95% CI: 1.10-1.77) | Juurlink et al[23] |
Retrospective cohort study | October 2003 and January 2006 | PPI: 5244; without PPI: 2961 | Death or rehospitalization for MI or unstable angina | Death or rehospitalization: non-PPI vs PPI groups: 20.8% vs 29.8% OR: 1.25 (95% CI: 1.11-1.41); omeprazole OR: 1.24 (95% CI: 1.08-1.41); rabeprazole OR: 2.83 (95% CI: 1.96-4.09) | Ho et al[24] |
Retrospective cohort study using the National Medco Integrated Database | 1 yr | PPI: 6828; without PPI: 9862 | Stroke or TIA, ACS, CV death, coronary revascularization | MACE rate in the PPI vs non-PPI groups: 25.1% vs 17.8% (adjusted HR of 1.57, 95% CI: 1.39-1.64); Omeprazole: 25.1% HR: 1.39 (95% CI: 1.22-1.57), esomeprazole: 24.9% HR: 1.57 (95% CI: 1.40-1.76), lansoprazole: 24.3% HR: 1.39 (95% CI: 1.16-1.67) and pantoprazole: 29.2% HR: 1.61 (95% CI: 1.44-1.81) | Kreutz et al[25] |
Retrospective cohort within RCT | 28 d and 1 yr | PPI: 366; without PPI: 1750 | Death, MI, stroke at 1 yr; Death, MI, UTVR at 28 d | Death, MI, stroke at 1 yr: HR: 1.55, 95% CI: 1.031-2.341, P = 0.035; Death, MI, UTVR at 28 d, HR: 1.63, 95% CI: 1.015-2.627, P = 0.043 | Dunn et al[46] |
Retrospective cohort study | 1 yr | PPI: 318; without PPI: 502 | CV death, Q-wave MI, coronary revascularization and stent thrombosis | Major MACE event rate in the PPI vs non-PPI groups: 13.8% vs 8% (P = 0.008); HR of MACE: 1.8 (95% CI: 1.1-2.7, P = 0.01); overall mortality: 4.7% vs 1.8% (P = 0.02) | Gaglia et al[48] |
Retrospective observational study (FRENA registry) | 15 mo | PPI: 519; no PPI: 703 | MI, stroke, critical limb ischemia, death | Incidence of events of PPI vs no PPI groups: MI: 4.4% vs 2.1%, HR: 2.5 (95% CI: 1.3-4.8, P = 0.003); stroke: 3.7% vs 2.3%, HR: 1.9 (95% CI: 1.03-3.7, P = 0.039); critical limb ischemia: 4.7% vs 3.4%; HR: 1.6 (95% CI: 0.95-2.8, P = 0.077); death: 7.5% vs 3.3%, HR: 2.2 (95% CI: 1.3-3.7, P = 0.003) | Muñoz-Torrero et al[49] |
Study design | Follow-up | Number of patients on clopidogrel with/without PPI | End point | Results | Ref. |
Cohort study | 12 yr | PPI: 83; no PPI: 176 | MI, CV death, urgent revascularization | No significant effect of use of PPIs | Collet et al[43] |
Retrospective cohort study | 180 d | PPI: 3996; no PPI: 14 569 | MI, death or coronary revascularization | Adjusted RR for MI or death: 1.22 (95% CI: 0.99-1.51); for revascularization, 0.97 (95% CI: 0.79-1.21) | Rassen et al[47] |
Retrospective cohort study | 1-yr | PPI: 397; no PPI: 138 | MI, death, CABG or repeat PCI | Death, MI events with PPI vs non-PPI groups: 6.7% vs 9.6% (P = 0.32); CABG with PPI vs non-PPI groups: 3.1% vs 4.1% (P = 0.53); revascularization with PPI vs non-PPI groups: 15.8% vs 14.2% (P = 0.65) | Ramirez et al[51] |
Prospective, double-blind placebo- controlled multicentre RCT | Median of 133 d | PPI: 1801; no PPI: 1826 | Cardiovascular events (death, non-fatal MI, CABG or PCI, or ischemic stroke) | Cardiovascular events: HR: 1.02, 95% CI: 0.70-1.51 | Bhatt et al[53] |
Double-blind randomized trial | 6 mo | PPI: 2257; no PPI: 4538 | MACE (CV death, MI, stroke) | MACE in PPI vs no PPI groups after adjustment for potential confounders: 11.8% vs 12.2%, adjusted HR: 0.94 (95% CI: 0.80-1.11, P = 0.46) | O’Donoghue et al[26] |
Retrospective cohort study (FAST-MI Registry) | 1 yr | PPI: 1453; no PPI: 900 | Death, MI, or stroke | No in-hospital difference in death, reinfarction, or major bleeding in PPI vs no PPI groups; Death, MI, or stroke at 1 yr in PPI. no PPI groups: 12% vs 14% (P = 0.72), adjusted OR: 0.98 (95% CI: 0.90-1.08) | Simon et al[54] |
- Citation: Lin SL, Chang HM, Liu CP, Chou LP, Chan JW. Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol 2011; 3(5): 153-164
- URL: https://www.wjgnet.com/1949-8462/full/v3/i5/153.htm
- DOI: https://dx.doi.org/10.4330/wjc.v3.i5.153